Wedbush Securities
CSCI

Wedbush Securities’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Wedbush Securities’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-794
Closed -$28K – 988
2020
Q3 		$28K Buy
794
+594
+297% +$26.3K ﹤0.01% 915
2020
Q2 		$16K Buy
+200
New +$18.3K ﹤0.01% 946

Other funds holding CSCI

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Federation des caisses Desjardins du Quebec
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
RFA
Reilly Financial Advisors La Mesa, California $1.35B AUM 22.65% 1-Year Est. Return
DWM
Dorchester Wealth Management Montreal, Quebec, Canada $501M AUM 16.39% 1-Year Est. Return

Wedbush Securities's CSCI Position: Q4 2020 in Review

Wedbush Securities sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q4 2020, closing a stake of 794 shares — an estimated $28K sold.

Wedbush Securities first reported a position in CSCI in Q2 2020 and held it in 2 quarters. The position peaked at $28K in Q3 2020. 20 funds tracked by Wall St. Rank hold CSCI as of Q4 2020.

  • Wedbush Securities reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 794 COSCIENS Biopharma Inc. Common Stock shares in Q4 2020, an estimated $28K.
  • Wedbush Securities first reported a position in COSCIENS Biopharma Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Wedbush Securities's COSCIENS Biopharma Inc. Common Stock position peaked at $28K in Q3 2020.
  • 20 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.